Steven F. Komjathy
Amgen (United States)(US)
Publications by Year
Research Areas
Parkinson's Disease Mechanisms and Treatments, Antifungal resistance and susceptibility, Neurological disorders and treatments, Cardiac Ischemia and Reperfusion, Pharmaceutical studies and practices
Most-Cited Works
- → The Potent BACE1 Inhibitor LY2886721 Elicits Robust Central Aβ Pharmacodynamic Responses in Mice, Dogs, and Humans(2015)199 cited
- → Phase 1 trial of a 13-valent pneumococcal conjugate vaccine in healthy adults(2007)107 cited
- → Best practices for the use of itraconazole as a replacement for ketoconazole in drug–drug interaction studies(2015)85 cited
- → Arterial diastolic pressure augmentation by intra-aortic balloon counterpulsation enhances the onset of coronary artery reperfusion by thrombolytic therapy.(1994)60 cited
- → Effect of Varying Amounts of a Liquid Nutritional Supplement on the Pharmacokinetics of Posaconazole in Healthy Volunteers(2009)54 cited
- → Orally inhaled levodopa (CVT-301) for early morning OFF periods in Parkinson's disease(2019)45 cited
- → Skin Concentrations and Pharmacokinetics of Posaconazole after Oral Administration(2010)27 cited
- → Pharmacokinetics, pharmacodynamics, and safety of clevidipine after prolonged continuous infusion in subjects with mild to moderate essential hypertension(2012)13 cited
- → Regional and systemic platelet function is altered by myocardial ischemia-reperfusion(1995)11 cited
- → 1219 THREE-DAY, DOSE-RANGING STUDY OF THE HCV NS5A INHIBITOR GS-5885(2011)11 cited